Clinical Trials

125 enrolled 18 charts 2 FDA

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02421939 2025-12-04

A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

371 enrolled 36 charts 2 FDA

Phase 3 Active not recruiting

Leukemia, Myeloid, Acute

NCT03173248 2025-11-10

AGILE

146 enrolled 11 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT03069352 2025-09-30

A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

211 enrolled 30 charts 2 FDA

Phase 3 Active not recruiting

Leukemia, Leukemia, Myeloid, Acute

NCT02993523 2025-08-19

Viale-a

443 enrolled 14 charts 2 FDA

Leukemia, Myeloid, Acute

NCT01757535 2025-07-08

QUAZAR AML-001

472 enrolled 24 charts 1 FDA

336 enrolled 48 charts 2 FDA

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Phase 1/2 Completed

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02074839 2025-06-08

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Phase 1 Recruiting

291 enrolled 4 FDA

345 enrolled 120 charts 1 FDA

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT01915498 2024-10-22

Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation

Phase 1/2 Completed

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

227 enrolled 37 charts 2 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02668653 2024-08-06

QuANTUM-First

539 enrolled 20 charts 2 FDA

138 enrolled 23 charts 2 FDA

Leukemia, Leukemia, Myeloid, Acute

NCT02113982 2024-08-01

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Phase 1/2 Completed

Blastic Plasmacytoid Dendritic Cell Neoplasm, Leukemia, Myeloid, Acute

NCT00372593 2021-03-24

Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia

1,070 enrolled 18 charts 1 FDA

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

NCT01696084 2020-08-10

301

309 enrolled 14 charts 1 FDA

Leukemia, Myeloid, Acute

NCT00822393 2020-07-30

Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)

570 enrolled 2 FDA

255 enrolled 82 charts 1 FDA

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01546038 2020-03-03

A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Phase 2 Completed

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00927498 2013-07-11

A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old

280 enrolled 1 FDA